JavaScript NENÍ povolen !

Prosím povolte JavaScript.

* Zobrazit nápovědu

Reset

Pracoviště: Niigata University Niigata Japan

1 záznamů v Medvik Filtry

Článek

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Motzer, Robert J
Autor Motzer, Robert J From Memorial Sloan Kettering Cancer Center, New York (R.J.M.), and Roswell Park Cancer Institute, Buffalo (S.G.) - both in New York University of Texas M.D. Anderson Cancer Center, Houston (N.M.T., P. Sharma) Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center (D.F.M.), and Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School (T.K.C.), Boston Centro Internacional de Estudios Clínicos (O.A.F.) and Fundación Arturo López Pérez (P. Salman), Santiago, Chile Palacký University and University Hospital Olomouc, Olomouc, Czech Republic (B.M.) Fox Chase Cancer Center, Philadelphia (E.R.P.) Hôpitaux Universitaires de Strasbourg, Strasbourg (P.B.), Bordeaux University Hospital, Hôpital Saint-André, Bordeaux (A.R.), and Institut Gustave Roussy, Villejuif (B.E.) - all in France Istituto di Ricovero e Cura a Carattere Scientifico San Matteo University Hospital Foundation, Pavia (C.P.), and Ospedale San Donato, Azienda Unità Sanitaria Locale Toscana Sud-Est, Istituto Toscano Tumori, Arezzo (S.B.) - both in Italy Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust (T.P.), and Cancer Research UK (R.H.), London Aarhus University Hospital, Aarhus, Denmark (F.D.) Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, and Tel Aviv University, Tel Aviv - both in Israel (V.N.) British Columbia Cancer Agency, Vancouver, Canada (C.K.K.) Westmead Hospital and Macquarie University, Sydney (H.G.) Jena University Hospital, Jena, Germany (M.-O.G.) Centro de Pesquisa em Oncologia, Hospital São Lucas, Porto Alegre, Brazil (C.H.B.) Niigata University, Niigata, Japan (Y.T.) Hospital Universitario 12 de Octubre, Madrid (D.C.) Cleveland Clinic Taussig Cancer Institute, Cleveland (B.I.R.) Bristol-Myers Squibb, Princeton, NJ (A.C.C., S.M., M.B.M., M.W.-R., J.D.) and Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore (H.J.H.)
Tannir, Nizar M
Autor Tannir, Nizar M From Memorial Sloan Kettering Cancer Center, New York (R.J.M.), and Roswell Park Cancer Institute, Buffalo (S.G.) - both in New York University of Texas M.D. Anderson Cancer Center, Houston (N.M.T., P. Sharma) Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center (D.F.M.), and Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School (T.K.C.), Boston Centro Internacional de Estudios Clínicos (O.A.F.) and Fundación Arturo López Pérez (P. Salman), Santiago, Chile Palacký University and University Hospital Olomouc, Olomouc, Czech Republic (B.M.) Fox Chase Cancer Center, Philadelphia (E.R.P.) Hôpitaux Universitaires de Strasbourg, Strasbourg (P.B.), Bordeaux University Hospital, Hôpital Saint-André, Bordeaux (A.R.), and Institut Gustave Roussy, Villejuif (B.E.) - all in France Istituto di Ricovero e Cura a Carattere Scientifico San Matteo University Hospital Foundation, Pavia (C.P.), and Ospedale San Donato, Azienda Unità Sanitaria Locale Toscana Sud-Est, Istituto Toscano Tumori, Arezzo (S.B.) - both in Italy Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust (T.P.), and Cancer Research UK (R.H.), London Aarhus University Hospital, Aarhus, Denmark (F.D.) Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, and Tel Aviv University, Tel Aviv - both in Israel (V.N.) British Columbia Cancer Agency, Vancouver, Canada (C.K.K.) Westmead Hospital and Macquarie University, Sydney (H.G.) Jena University Hospital, Jena, Germany (M.-O.G.) Centro de Pesquisa em Oncologia, Hospital São Lucas, Porto Alegre, Brazil (C.H.B.) Niigata University, Niigata, Japan (Y.T.) Hospital Universitario 12 de Octubre, Madrid (D.C.) Cleveland Clinic Taussig Cancer Institute, Cleveland (B.I.R.) Bristol-Myers Squibb, Princeton, NJ (A.C.C., S.M., M.B.M., M.W.-R., J.D.) and Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore (H.J.H.)
McDermott, David F
Autor McDermott, David F From Memorial Sloan Kettering Cancer Center, New York (R.J.M.), and Roswell Park Cancer Institute, Buffalo (S.G.) - both in New York University of Texas M.D. Anderson Cancer Center, Houston (N.M.T., P. Sharma) Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center (D.F.M.), and Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School (T.K.C.), Boston Centro Internacional de Estudios Clínicos (O.A.F.) and Fundación Arturo López Pérez (P. Salman), Santiago, Chile Palacký University and University Hospital Olomouc, Olomouc, Czech Republic (B.M.) Fox Chase Cancer Center, Philadelphia (E.R.P.) Hôpitaux Universitaires de Strasbourg, Strasbourg (P.B.), Bordeaux University Hospital, Hôpital Saint-André, Bordeaux (A.R.), and Institut Gustave Roussy, Villejuif (B.E.) - all in France Istituto di Ricovero e Cura a Carattere Scientifico San Matteo University Hospital Foundation, Pavia (C.P.), and Ospedale San Donato, Azienda Unità Sanitaria Locale Toscana Sud-Est, Istituto Toscano Tumori, Arezzo (S.B.) - both in Italy Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust (T.P.), and Cancer Research UK (R.H.), London Aarhus University Hospital, Aarhus, Denmark (F.D.) Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, and Tel Aviv University, Tel Aviv - both in Israel (V.N.) British Columbia Cancer Agency, Vancouver, Canada (C.K.K.) Westmead Hospital and Macquarie University, Sydney (H.G.) Jena University Hospital, Jena, Germany (M.-O.G.) Centro de Pesquisa em Oncologia, Hospital São Lucas, Porto Alegre, Brazil (C.H.B.) Niigata University, Niigata, Japan (Y.T.) Hospital Universitario 12 de Octubre, Madrid (D.C.) Cleveland Clinic Taussig Cancer Institute, Cleveland (B.I.R.) Bristol-Myers Squibb, Princeton, NJ (A.C.C., S.M., M.B.M., M.W.-R., J.D.) and Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore (H.J.H.)
Arén Frontera, Osvaldo
Autor Arén Frontera, Osvaldo From Memorial Sloan Kettering Cancer Center, New York (R.J.M.), and Roswell Park Cancer Institute, Buffalo (S.G.) - both in New York University of Texas M.D. Anderson Cancer Center, Houston (N.M.T., P. Sharma) Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center (D.F.M.), and Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School (T.K.C.), Boston Centro Internacional de Estudios Clínicos (O.A.F.) and Fundación Arturo López Pérez (P. Salman), Santiago, Chile Palacký University and University Hospital Olomouc, Olomouc, Czech Republic (B.M.) Fox Chase Cancer Center, Philadelphia (E.R.P.) Hôpitaux Universitaires de Strasbourg, Strasbourg (P.B.), Bordeaux University Hospital, Hôpital Saint-André, Bordeaux (A.R.), and Institut Gustave Roussy, Villejuif (B.E.) - all in France Istituto di Ricovero e Cura a Carattere Scientifico San Matteo University Hospital Foundation, Pavia (C.P.), and Ospedale San Donato, Azienda Unità Sanitaria Locale Toscana Sud-Est, Istituto Toscano Tumori, Arezzo (S.B.) - both in Italy Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust (T.P.), and Cancer Research UK (R.H.), London Aarhus University Hospital, Aarhus, Denmark (F.D.) Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, and Tel Aviv University, Tel Aviv - both in Israel (V.N.) British Columbia Cancer Agency, Vancouver, Canada (C.K.K.) Westmead Hospital and Macquarie University, Sydney (H.G.) Jena University Hospital, Jena, Germany (M.-O.G.) Centro de Pesquisa em Oncologia, Hospital São Lucas, Porto Alegre, Brazil (C.H.B.) Niigata University, Niigata, Japan (Y.T.) Hospital Universitario 12 de Octubre, Madrid (D.C.) Cleveland Clinic Taussig Cancer Institute, Cleveland (B.I.R.) Bristol-Myers Squibb, Princeton, NJ (A.C.C., S.M., M.B.M., M.W.-R., J.D.) and Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore (H.J.H.)
Melichar, Bohuslav
Autor Melichar, Bohuslav From Memorial Sloan Kettering Cancer Center, New York (R.J.M.), and Roswell Park Cancer Institute, Buffalo (S.G.) - both in New York University of Texas M.D. Anderson Cancer Center, Houston (N.M.T., P. Sharma) Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center (D.F.M.), and Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School (T.K.C.), Boston Centro Internacional de Estudios Clínicos (O.A.F.) and Fundación Arturo López Pérez (P. Salman), Santiago, Chile Palacký University and University Hospital Olomouc, Olomouc, Czech Republic (B.M.) Fox Chase Cancer Center, Philadelphia (E.R.P.) Hôpitaux Universitaires de Strasbourg, Strasbourg (P.B.), Bordeaux University Hospital, Hôpital Saint-André, Bordeaux (A.R.), and Institut Gustave Roussy, Villejuif (B.E.) - all in France Istituto di Ricovero e Cura a Carattere Scientifico San Matteo University Hospital Foundation, Pavia (C.P.), and Ospedale San Donato, Azienda Unità Sanitaria Locale Toscana Sud-Est, Istituto Toscano Tumori, Arezzo (S.B.) - both in Italy Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust (T.P.), and Cancer Research UK (R.H.), London Aarhus University Hospital, Aarhus, Denmark (F.D.) Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, and Tel Aviv University, Tel Aviv - both in Israel (V.N.) British Columbia Cancer Agency, Vancouver, Canada (C.K.K.) Westmead Hospital and Macquarie University, Sydney (H.G.) Jena University Hospital, Jena, Germany (M.-O.G.) Centro de Pesquisa em Oncologia, Hospital São Lucas, Porto Alegre, Brazil (C.H.B.) Niigata University, Niigata, Japan (Y.T.) Hospital Universitario 12 de Octubre, Madrid (D.C.) Cleveland Clinic Taussig Cancer Institute, Cleveland (B.I.R.) Bristol-Myers Squibb, Princeton, NJ (A.C.C., S.M., M.B.M., M.W.-R., J.D.) and Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore (H.J.H.)
Choueiri, Toni K
Autor Choueiri, Toni K From Memorial Sloan Kettering Cancer Center, New York (R.J.M.), and Roswell Park Cancer Institute, Buffalo (S.G.) - both in New York University of Texas M.D. Anderson Cancer Center, Houston (N.M.T., P. Sharma) Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center (D.F.M.), and Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School (T.K.C.), Boston Centro Internacional de Estudios Clínicos (O.A.F.) and Fundación Arturo López Pérez (P. Salman), Santiago, Chile Palacký University and University Hospital Olomouc, Olomouc, Czech Republic (B.M.) Fox Chase Cancer Center, Philadelphia (E.R.P.) Hôpitaux Universitaires de Strasbourg, Strasbourg (P.B.), Bordeaux University Hospital, Hôpital Saint-André, Bordeaux (A.R.), and Institut Gustave Roussy, Villejuif (B.E.) - all in France Istituto di Ricovero e Cura a Carattere Scientifico San Matteo University Hospital Foundation, Pavia (C.P.), and Ospedale San Donato, Azienda Unità Sanitaria Locale Toscana Sud-Est, Istituto Toscano Tumori, Arezzo (S.B.) - both in Italy Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust (T.P.), and Cancer Research UK (R.H.), London Aarhus University Hospital, Aarhus, Denmark (F.D.) Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, and Tel Aviv University, Tel Aviv - both in Israel (V.N.) British Columbia Cancer Agency, Vancouver, Canada (C.K.K.) Westmead Hospital and Macquarie University, Sydney (H.G.) Jena University Hospital, Jena, Germany (M.-O.G.) Centro de Pesquisa em Oncologia, Hospital São Lucas, Porto Alegre, Brazil (C.H.B.) Niigata University, Niigata, Japan (Y.T.) Hospital Universitario 12 de Octubre, Madrid (D.C.) Cleveland Clinic Taussig Cancer Institute, Cleveland (B.I.R.) Bristol-Myers Squibb, Princeton, NJ (A.C.C., S.M., M.B.M., M.W.-R., J.D.) and Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore (H.J.H.)
Plimack, Elizabeth R
Autor Plimack, Elizabeth R From Memorial Sloan Kettering Cancer Center, New York (R.J.M.), and Roswell Park Cancer Institute, Buffalo (S.G.) - both in New York University of Texas M.D. Anderson Cancer Center, Houston (N.M.T., P. Sharma) Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center (D.F.M.), and Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School (T.K.C.), Boston Centro Internacional de Estudios Clínicos (O.A.F.) and Fundación Arturo López Pérez (P. Salman), Santiago, Chile Palacký University and University Hospital Olomouc, Olomouc, Czech Republic (B.M.) Fox Chase Cancer Center, Philadelphia (E.R.P.) Hôpitaux Universitaires de Strasbourg, Strasbourg (P.B.), Bordeaux University Hospital, Hôpital Saint-André, Bordeaux (A.R.), and Institut Gustave Roussy, Villejuif (B.E.) - all in France Istituto di Ricovero e Cura a Carattere Scientifico San Matteo University Hospital Foundation, Pavia (C.P.), and Ospedale San Donato, Azienda Unità Sanitaria Locale Toscana Sud-Est, Istituto Toscano Tumori, Arezzo (S.B.) - both in Italy Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust (T.P.), and Cancer Research UK (R.H.), London Aarhus University Hospital, Aarhus, Denmark (F.D.) Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, and Tel Aviv University, Tel Aviv - both in Israel (V.N.) British Columbia Cancer Agency, Vancouver, Canada (C.K.K.) Westmead Hospital and Macquarie University, Sydney (H.G.) Jena University Hospital, Jena, Germany (M.-O.G.) Centro de Pesquisa em Oncologia, Hospital São Lucas, Porto Alegre, Brazil (C.H.B.) Niigata University, Niigata, Japan (Y.T.) Hospital Universitario 12 de Octubre, Madrid (D.C.) Cleveland Clinic Taussig Cancer Institute, Cleveland (B.I.R.) Bristol-Myers Squibb, Princeton, NJ (A.C.C., S.M., M.B.M., M.W.-R., J.D.) and Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore (H.J.H.)
Barthélémy, Philippe
Autor Barthélémy, Philippe From Memorial Sloan Kettering Cancer Center, New York (R.J.M.), and Roswell Park Cancer Institute, Buffalo (S.G.) - both in New York University of Texas M.D. Anderson Cancer Center, Houston (N.M.T., P. Sharma) Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center (D.F.M.), and Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School (T.K.C.), Boston Centro Internacional de Estudios Clínicos (O.A.F.) and Fundación Arturo López Pérez (P. Salman), Santiago, Chile Palacký University and University Hospital Olomouc, Olomouc, Czech Republic (B.M.) Fox Chase Cancer Center, Philadelphia (E.R.P.) Hôpitaux Universitaires de Strasbourg, Strasbourg (P.B.), Bordeaux University Hospital, Hôpital Saint-André, Bordeaux (A.R.), and Institut Gustave Roussy, Villejuif (B.E.) - all in France Istituto di Ricovero e Cura a Carattere Scientifico San Matteo University Hospital Foundation, Pavia (C.P.), and Ospedale San Donato, Azienda Unità Sanitaria Locale Toscana Sud-Est, Istituto Toscano Tumori, Arezzo (S.B.) - both in Italy Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust (T.P.), and Cancer Research UK (R.H.), London Aarhus University Hospital, Aarhus, Denmark (F.D.) Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, and Tel Aviv University, Tel Aviv - both in Israel (V.N.) British Columbia Cancer Agency, Vancouver, Canada (C.K.K.) Westmead Hospital and Macquarie University, Sydney (H.G.) Jena University Hospital, Jena, Germany (M.-O.G.) Centro de Pesquisa em Oncologia, Hospital São Lucas, Porto Alegre, Brazil (C.H.B.) Niigata University, Niigata, Japan (Y.T.) Hospital Universitario 12 de Octubre, Madrid (D.C.) Cleveland Clinic Taussig Cancer Institute, Cleveland (B.I.R.) Bristol-Myers Squibb, Princeton, NJ (A.C.C., S.M., M.B.M., M.W.-R., J.D.) and Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore (H.J.H.)
Porta, Camillo
Autor Porta, Camillo From Memorial Sloan Kettering Cancer Center, New York (R.J.M.), and Roswell Park Cancer Institute, Buffalo (S.G.) - both in New York University of Texas M.D. Anderson Cancer Center, Houston (N.M.T., P. Sharma) Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center (D.F.M.), and Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School (T.K.C.), Boston Centro Internacional de Estudios Clínicos (O.A.F.) and Fundación Arturo López Pérez (P. Salman), Santiago, Chile Palacký University and University Hospital Olomouc, Olomouc, Czech Republic (B.M.) Fox Chase Cancer Center, Philadelphia (E.R.P.) Hôpitaux Universitaires de Strasbourg, Strasbourg (P.B.), Bordeaux University Hospital, Hôpital Saint-André, Bordeaux (A.R.), and Institut Gustave Roussy, Villejuif (B.E.) - all in France Istituto di Ricovero e Cura a Carattere Scientifico San Matteo University Hospital Foundation, Pavia (C.P.), and Ospedale San Donato, Azienda Unità Sanitaria Locale Toscana Sud-Est, Istituto Toscano Tumori, Arezzo (S.B.) - both in Italy Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust (T.P.), and Cancer Research UK (R.H.), London Aarhus University Hospital, Aarhus, Denmark (F.D.) Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, and Tel Aviv University, Tel Aviv - both in Israel (V.N.) British Columbia Cancer Agency, Vancouver, Canada (C.K.K.) Westmead Hospital and Macquarie University, Sydney (H.G.) Jena University Hospital, Jena, Germany (M.-O.G.) Centro de Pesquisa em Oncologia, Hospital São Lucas, Porto Alegre, Brazil (C.H.B.) Niigata University, Niigata, Japan (Y.T.) Hospital Universitario 12 de Octubre, Madrid (D.C.) Cleveland Clinic Taussig Cancer Institute, Cleveland (B.I.R.) Bristol-Myers Squibb, Princeton, NJ (A.C.C., S.M., M.B.M., M.W.-R., J.D.) and Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore (H.J.H.)
George, Saby
Autor George, Saby From Memorial Sloan Kettering Cancer Center, New York (R.J.M.), and Roswell Park Cancer Institute, Buffalo (S.G.) - both in New York University of Texas M.D. Anderson Cancer Center, Houston (N.M.T., P. Sharma) Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center (D.F.M.), and Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School (T.K.C.), Boston Centro Internacional de Estudios Clínicos (O.A.F.) and Fundación Arturo López Pérez (P. Salman), Santiago, Chile Palacký University and University Hospital Olomouc, Olomouc, Czech Republic (B.M.) Fox Chase Cancer Center, Philadelphia (E.R.P.) Hôpitaux Universitaires de Strasbourg, Strasbourg (P.B.), Bordeaux University Hospital, Hôpital Saint-André, Bordeaux (A.R.), and Institut Gustave Roussy, Villejuif (B.E.) - all in France Istituto di Ricovero e Cura a Carattere Scientifico San Matteo University Hospital Foundation, Pavia (C.P.), and Ospedale San Donato, Azienda Unità Sanitaria Locale Toscana Sud-Est, Istituto Toscano Tumori, Arezzo (S.B.) - both in Italy Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust (T.P.), and Cancer Research UK (R.H.), London Aarhus University Hospital, Aarhus, Denmark (F.D.) Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, and Tel Aviv University, Tel Aviv - both in Israel (V.N.) British Columbia Cancer Agency, Vancouver, Canada (C.K.K.) Westmead Hospital and Macquarie University, Sydney (H.G.) Jena University Hospital, Jena, Germany (M.-O.G.) Centro de Pesquisa em Oncologia, Hospital São Lucas, Porto Alegre, Brazil (C.H.B.) Niigata University, Niigata, Japan (Y.T.) Hospital Universitario 12 de Octubre, Madrid (D.C.) Cleveland Clinic Taussig Cancer Institute, Cleveland (B.I.R.) Bristol-Myers Squibb, Princeton, NJ (A.C.C., S.M., M.B.M., M.W.-R., J.D.) and Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore (H.J.H.)

The New England journal of medicine. 2018 ; 378 (14) : 1277-1290. [pub] 20180321

N Engl J Med
ISSN 1533-4406
Medvik
Zdroj

BACKGROUND: Nivolumab plus ipilimumab produced objective responses in patients with advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus ipilimumab with sunitinib for previously untreated clear-cell advanced renal-cell carcinoma. METHODS: We randomly assigned adults in a 1:1 ratio to receive either nivolumab (3 mg per kilogram of body weight) plus ipilimumab (1 mg per kilogram) intravenously every 3 weeks for four doses, followed by nivolumab (3 mg per kilogram) every 2 weeks, or sunitinib (50 mg) orally once daily for 4 weeks (6-week cycle). The coprimary end points were overall survival (alpha level, 0.04), objective response rate (alpha level, 0.001), and progression-free survival (alpha level, 0.009) among patients with intermediate or poor prognostic risk. RESULTS: A total of 1096 patients were assigned to receive nivolumab plus ipilimumab (550 patients) or sunitinib (546 patients); 425 and 422, respectively, had intermediate or poor risk. At a median follow-up of 25.2 months in intermediate- and poor-risk patients, the 18-month overall survival rate was 75% (95% confidence interval [CI], 70 to 78) with nivolumab plus ipilimumab and 60% (95% CI, 55 to 65) with sunitinib; the median overall survival was not reached with nivolumab plus ipilimumab versus 26.0 months with sunitinib (hazard ratio for death, 0.63; P<0.001). The objective response rate was 42% versus 27% (P<0.001), and the complete response rate was 9% versus 1%. The median progression-free survival was 11.6 months and 8.4 months, respectively (hazard ratio for disease progression or death, 0.82; P=0.03, not significant per the prespecified 0.009 threshold). Treatment-related adverse events occurred in 509 of 547 patients (93%) in the nivolumab-plus-ipilimumab group and 521 of 535 patients (97%) in the sunitinib group; grade 3 or 4 events occurred in 250 patients (46%) and 335 patients (63%), respectively. Treatment-related adverse events leading to discontinuation occurred in 22% and 12% of the patients in the respective groups. CONCLUSIONS: Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate- and poor-risk patients with previously untreated advanced renal-cell carcinoma. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 214 ClinicalTrials.gov number, NCT02231749 .).

Kolekce

Publikováno

Filtry

* Zobrazit nápovědu

* Zobrazit nápovědu

Upřesnit dle MeSH